Clinical Features of Nontuberculous Mycobacterial Pleurisy: A Review of 12 Cases

Maiko Naito¹, Toshiya Maekura¹, Yu Kurahara¹, Masahiro Tahara¹, Naoya Ikegami¹, Yohei Kimura¹, Shoko Sonobe¹, Takehiho Kobayashi¹, Shojiro Minomo¹, Taisuke Tsuji¹, Kazunari Tsuyuguchi², Seiji Hayashi¹ and Katsuhiro Suzuki¹

Abstract:
Objective The incidence of pulmonary nontuberculous mycobacterial (NTM) infections has increased in recent decades. Nevertheless, NTM pleurisy is still a rare disease. The objective of the present study was to elucidate the clinical features and outcomes of NTM pleurisy.
Methods A retrospective study was undertaken of consecutive patients whose pleural effusion culture yielded NTM, from 2002 to 2016 at a respiratory hospital in Japan. The clinical features, treatment, and outcomes of these patients were analyzed.
Result The 12 patients with NTM pleurisy were predominantly male, with a median age of 69 years (range, 48-93 years). They included eight patients with a history of smoking and six patients with immunosuppressive comorbidities such as malignancy, diabetes mellitus, and conditions requiring steroid administration. Fibrocavitary disease was the most common radiographic feature of these patients, and Mycobacterium avium complex was the most common pathogen. Pneumothorax was complicated in 11 patients. Surgery was performed on seven patients, in addition to thoracic drainage for the treatment of pleurisy and pneumothorax. Three patients died of respiratory failure.
Conclusion Pneumothorax is a frequent complication of NTM pleurisy, often making the condition difficult to treat. Surgery at an appropriate time should therefore be considered for refractory cases.
Key words: nontuberculous mycobacterium, pleurisy, pneumothorax

Introduction
Pulmonary nontuberculous mycobacterial (NTM) infections have been increasing worldwide in the past few decades (1-3). Although the precise reasons for this phenomenon have not yet been clearly elucidated, possible contributory factors include the increase of aging populations and various immunocompromised conditions, as well as an enhanced recognition of NTM and improvements in bacterial detection techniques (4). NTM-related mortality is also reported to be increasing (5). Although pulmonary NTM infection is often chronic, some patients may experience rapidly progressive disease (6).

NTM pleurisy is suspected to have a high mortality rate, but it is rarely seen compared to pleurisy caused by Mycobacterium tuberculosis (7). Because of its rarity, the clinical features of NTM pleurisy remain unknown. We therefore conducted a retrospective study, to elucidate the clinical features and outcomes of NTM pleurisy.

Materials and Methods
Study subjects
We reviewed the mycobacterial laboratory registry data-
Each patient was not required. The clinical characteristics, treatment course, and outcomes of NTM pleurisy patients were analyzed. Pulmonary NTM infection was defined according to American Thoracic Society/Infectious Diseases Society of America guidelines (6).

This study was approved by the institutional review board of our hospital. (Approval number: 555) Since all data were collected retrospectively, obtaining informed consent from each patient was not required.

Table 1. Patient Characteristics (n=12).

| Characteristic                         | Value                  |
|----------------------------------------|------------------------|
| Age, years, median (range)             | 69 (48-93)             |
| Sex                                    |                        |
| Male                                   | 9                      |
| Female                                 | 3                      |
| Smoking history                        |                        |
| Yes                                    | 8                      |
| No                                     | 4                      |
| Immunosuppressed factor                |                        |
| Malignancy                             | 1                      |
| Diabetes mellitus                      | 4                      |
| Steroid administration                | 3                      |
| Body mass index, kg/m², median (range) | 21.2 (15.4-22.5)       |
| WBC, /μL                               | 7,500 (2,100-14,200)   |
| Hb, g/dL                               | 11.8 (8.5-14.5)        |
| TP, g/dL                               | 7.1 (5.2-7.9)          |
| Alb, g/dL                              | 3.2 (2.1-4.2)          |
| CRP, mg/dL                             | 7.1 (2.2-26.9)         |
| Appearance of pleural effusion         |                        |
| Yellow                                 | 4                      |
| Bloody                                 | 1                      |
| Purulent                               | 1                      |
| Unknown                                | 6                      |
| Predominant cell of pleural effusion   |                        |
| Lymphocyte                             | 5                      |
| Neutrophil                             | 2                      |
| Unknown                                | 5                      |
| Laboratory (pleural effusion)          |                        |
| pH                                     | 7.2 (7.0-7.4)          |
| LDH, U/L                               | 760 (256-8,970)        |
| Glucose, mg/dL                         | 93 (1-238)             |
| Total protein, g/dL                    | 4.2 (3.3-5.2)          |
| ADA, U/L                               | 59.8 (29.8-73.2)       |

Table 2. Radiologic Findings (n=12).

| Disease type | Value |
|--------------|-------|
| NB           | 3     |
| FC           | 5     |
| Unknown      | 4     |

| Cavity       | Value |
|--------------|-------|
| Right        | 6     |
| Left         | 0     |
| Bilateral    | 2     |
| Unknown      | 4     |

| Pneumothorax | Value |
|--------------|-------|
| Right        | 8     |
| Left         | 3     |
| None         | 1     |

NB: nodular/bronchiectatic disease, FC: fibrocavitary disease

**Radiographic assessment**

Computed tomography (CT) findings were evaluated by three trained pulmonologists. The two major radiological findings diagnostic of pulmonary NTM infection were fibrocavitary (FC) disease and nodular/bronchiectatic (NB) disease (6). Upper lung field fibrocavitary lesions, a tuberculosis like pattern, were defined as FC disease, while multiple nodules and bronchiectasis, typically seen in the middle lobe or lingula, were defined as NB disease (8). The type of pulmonary NTM infection, and the presence of cavitary lesions and pneumothorax were also analyzed.

**Results**

During the study period, 4097 PE samples were sent for mycobacterial culture. Among these samples, 14 PE samples yielded NTM. Since the medical records of two of these patients were not available, they were excluded from the study, and the clinical manifestations of 12 patients were analyzed. All of these 12 patients were accompanied by clinical symptoms and elevated serum inflammatory markers.

The patient characteristics are shown in Table 1. The median age was 69 years, and they included nine men and three women. Of these, eight patients had a history of smoking, and six patients had immunosuppressive comorbidities such as malignancy, diabetes mellitus, and conditions requiring steroid administration. The median body mass index was 21.2 kg/m², and the median serum albumin level was 3.2 g/dL. One patient had a purulent PE suggesting empyema. The median adenosine deaminase level of PE was 59.8 U/L. Lymphocyte predominated in five samples and neutrophils in two samples.

**Radiological findings**

The findings from CT images are shown in Table 2. The most common NTM disease type seen was FC disease (five patients); NB disease was seen in four patients. Emphyse-
matous lesions were seen in four patients, all of whom were smokers. Cavitary lesions due to pulmonary NTM were seen in eight patients. Pneumothorax was seen in 11 out of 12 patients, and pleurisy always occurred on the same side as pneumothorax.

**NTM species and courses of treatment**

The NTM species yielded from the PE were *Mycobacterium avium* in five patients, *M. intracellulare* in three, *M. kansasii* in two, *M. abscessus* in one, and *M. chelonae* in one (Table 3). Before the onset of NTM pleurisy, eight patients had received anti-NTM medication, and the time from the diagnosis of pulmonary NTM disease until the onset of pleurisy varied widely from simultaneously to more than 18 years. As described above, pneumothorax was a complication in 11 patients. Only two patients were cured via anti-NTM medication and thoracic drainage alone. Surgery was performed on seven patients, three of whom required multiple operations. Open-window thoracotomy was performed on three patients, debridement on two, and thoracotomy for pneumothorax on four. Granulomatous inflammation was seen in the resected tissue of three patients.

In spite of performing multidisciplinary treatment, three out of 12 patients died. One of these three patients had been suffering from small cell lung cancer when NTM pleurisy occurred. Since the patient’s general condition was poor, surgery was not indicated; the coexistence of pneumothorax, NTM pleurisy and lung cancer let to fatal respiratory failure in that case. The other two patients who died were on medication for chronic refractory pulmonary NTM infection; the response to the medication was poor, and they developed NTM pleurisy. Surgery was performed on one patient, but it was not indicated for the other. Eventually, both died of progressive respiratory failure.

**Table 3. Patients with Nontuberculosis Pleurisy (n=12)**

| Case | Age | Sex | Mycobacterium species(Pe) | Medication before onset | Medication after onset | Time until onset of pleurisy from diagnosis of NTM species | Outcome |
|------|-----|-----|---------------------------|------------------------|----------------------|---------------------------------------------------------|---------|
| 1    | 59  | M   | *M. kansasii*              | INH, RFP, EB, PZA      | RFP, EB, PZA         | 4 years before onset                                      | Improved |
| 2    | 69  | M   | *M. abscessus*             | INH, RFP, EB, PZA      | RFP, EB, CAM         | 4 years before onset                                      | Improved |
| 3    | 72  | M   | *M. avium*                 | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 4    | 60  | F   | *M. intracellulare*        | RFP, EB, CAM           | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 5    | 77  | M   | *M. abscessus*             | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 6    | 48  | M   | *M. intracellulare*        | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 7    | 69  | F   | *M. intracellulare*        | RFP, EB, CAM           | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 8    | 71  | M   | *M. abscessus*             | RFP, EB, CAM           | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 9    | 84  | M   | *M. intracellulare*        | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 10   | 61  | F   | *M. intracellulare*        | RFP, EB, CAM           | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 11   | 66  | M   | *M. intracellulare*        | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |
| 12   | 66  | M   | *M. intracellulare*        | INH, RFP, EB, PZA      | RFP, EB, CAM         | 1 year before onset                                       | Improved |

**Discussion**

Although pleurisy is an uncommon complication of pulmonary NTM disease (9-12), it has become a clinical concern because of the increasing prevalence of NTM disease. During the 13-year study period at our hospital, NTM was isolated from PEs in 14 patients.

In our study, NTM pleurisy was more common in men than in women. Furthermore, FC disease was seen slightly more frequently than NB disease. FC disease is more common in older male smokers, while NB disease more frequently occurs in middle-aged or older women with no smoking history (1). The prevalence of NB disease in Japanese women has increased in the past few decades, and it is now the most common type of pulmonary NTM disease (13, 14). However, in the present study, male patients with FC disease were more frequently seen. A male sex, the presence of systemic and/or respiratory comorbidities, and non-NB radiographical features are reported to be negative prognostic factors for pulmonary *M. avium* complex disease (8). These factors may overlap with the characteristics
often seen in NTM pleurisy patients.

How the NTM infection reaches pleural effusion has not yet been adequately explained; however, there are two hypotheses regarding the pathway: The first hypothesized mechanism is the infiltration of the infectious pulmonary lesion; the second is the leakage of NTM bacteria from the pulmonary lesion to the thorax through perforating foci, such as those present in pneumothorax (15). In our research, 11 out of 12 patients had pneumothorax. In spite of NTM pleurisy without pneumothorax being reported (7), pneumothorax may be one of the causes of NTM pleurisy. Since cavitary lesions were often seen in our research, pulmonary NTM disease itself may sometimes cause pneumothorax, as well as underlying respiratory disease. In fact, pneumothorax due to the perforation of cavity lesions caused by NTM infection has been reported, which was also demonstrated in specimens resected by surgery (16).

Anti-NTM chemotherapy is generally associated with better outcomes for the treatment of NTM pleurisy (6). Nevertheless, cases of NTM infection that are difficult to treat medically are often seen in clinical practice and are also reported (5, 6). Since most of the patients were complicated with pneumothorax, surgery was necessary in addition to medication and thoracic drainage. According to our research, NTM pleurisy with pneumothorax tends to have a poor prognosis. For those with a poor general condition and infection due to mycobacterial species resistant to chemotherapy, NTM pleurisy and pneumothorax may be fatal. Even those with mild underlying disease may require several operations to achieve successful treatment. Therefore, timely surgery might be needed to cure NTM pleurisy with pneumothorax before the patient’s condition worsens.

There are several limitations associated with this study. First, as this was a retrospective study, some clinical and laboratory records were not available. Moreover, the number of patients with NTM pleurisy may have been underestimated, since mild pleural effusion was not routinely investigated and a mycobacterial culture was not performed on every PE sample. Lastly, we studied only a small number of patients at a single institution; in order to obtain more information about NTM pleurisy, large-scale studies are needed.

**Conclusion**

NTM pleurisy may occur in men with a history of smoking and the radiological features of FC disease. The treatment of NTM pleurisy is especially difficult when pneumothorax is complicated. If thoracic drainage and medication are ineffective, then surgery should be considered without delay.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 133: 243-251, 2008.
2. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacteria: current state and new insights. Chest 148: 1517-1527, 2015.
3. Kim JS, Tanaka N, Newell JD, et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 128: 3863-3969, 2005.
4. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest 129: 1653-1672, 2006.
5. Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosiysis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 11: 1-8, 2014.
6. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416, 2007.
7. Shu CC, Lee LN, Wang JT, et al; Taiwan Anti-Mycobacteria Investigation (TAMI) Group. Non-tuberculous mycobacterial pleurisy: an 8-year single-centre experience in Taiwan. Int J Tuberc Lung Dis 14: 635-641, 2010.
8. Hayashi M, Takayanagi N, Kanauchi T, et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 185: 575-583, 2012.
9. Ichiki H, Ueda S, Watanabe A, et al. Nontuberculous pulmonary mycobacteriosiysis complicated by pleuritis. NIHon Kokyuki Gakkai Zasshi 49: 885-889, 2011 (in Japanese, Abstract in English).
10. Park SU, Koh WJ, Kwon OJ, et al. Acute pneumonia and empyema caused by Mycobacterium intracellulare. Intern Med 45: 1007-1010, 2006.
11. Hayashi T, Takayama S, Tominaga S, et al. A case of pyothorax caused by Mycobacterium avium. NIHon Kokyuki Gakkai Zasshi 44: 117-121, 2006 (in Japanese, Abstract in English).
12. Orihashi T, Yatera K, Matsuo M, et al. A case of successfully treated pulmonary Mycobacterium abscessus infection associated with empyema thoracis. NIHon Kokyuki Gakkai Zasshi 1: 213-218, 2012 (in Japanese, Abstract in English).
13. Tanaka E, Amitani R, Niimi A, et al. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 155: 2041-2046, 1997.
14. Okumura M, Iwai K, Ogata H, et al. Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med 47: 1465-1472, 2008.
15. Kotani K, Hirose Y, Endo S, Yamamoto H, Makihara S. Surgical treatment of atypical Mycobacterium intracellulare infection with chronic empyema: a case report. J Thorac Cardiovasc Surg 130: 907-908, 2005.
16. Hagiwara E, Shiihara J, Enomoto T, et al. Clinical features of pneumothorax in patients with active nontuberculous mycobacterial lung disease. NIHon Kokyuki Gakkai Zasshi 48: 104-107, 2010 (in Japanese, Abstract in English).

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).